Zymvol Biomodeling is a technology company.
Zymvol Biomodeling has raised $3.0M across 1 funding round.
Zymvol Biomodeling has raised $3.0M in total across 1 funding round.
Zymvol Biomodeling has raised $3.0M in total across 1 funding round.
Zymvol Biomodeling's investors include Austin Walne, Elkstone, Faber, LGF, Pareto Holdings.
Zymvol Biomodeling is a Barcelona-based biotech company founded in 2017 that designs and discovers industrial enzymes using an AI-Physics hybrid approach combined with molecular modeling and bioinformatics.[1][2][3] It serves R&D managers in diverse industries by accelerating the shift from traditional chemical processes to sustainable biocatalytic ones, solving problems like lengthy trial-and-error enzyme engineering, low yields, and overlooked opportunities through rapid in silico screening that reduces millions of leads to top performers.[2][4] The company has demonstrated growth momentum, including a €3 million seed funding round in February 2025 led by Faber and Elaia Partners, building on its pioneering work since 2017 to democratize green chemistry.[5][7]
Zymvol Biomodeling was established in 2017 in Barcelona, Spain, by a team of scientists and entrepreneurs with deep expertise in enzyme development and biomanufacturing.[1][2][3] Key founders include a scientist-entrepreneur with over 20 years in computer-guided enzyme development (2020 EU Women Innovators prize recipient), the former Head of Biotech at Solvay with 20+ years delivering 14 molecules to market and managing $120M projects, and experts from institutions like Universitat Autònoma de Barcelona (UAB), Barcelona Supercomputing Center, and University of Padova.[3] The idea emerged from leveraging bioinformatics, molecular modeling, and AI to streamline enzyme innovation, addressing inefficiencies in traditional directed evolution methods that plateau after multiple rounds.[2] Early traction came from in-house platform development and partnerships with leading biotechs, evolving into cloud-based simulations for biocatalytic solutions.[6]
Zymvol rides the wave of sustainable biotech and green chemistry, where biocatalysis replaces energy-intensive chemical processes amid rising regulatory pressures for eco-friendly manufacturing and net-zero goals.[1][2] Timing is ideal post-2025 funding, as AI advancements in protein design (e.g., LLMs for enzymes) converge with industrial demands for circular economy solutions in sectors like materials, pharma, and manufacturing.[3][5] Market forces favoring Zymvol include EU innovation grants, corporate sustainability mandates, and the shift to computational biology, amplified by its Barcelona hub in Europe's biotech ecosystem.[1][5] It influences the landscape by democratizing enzyme tech, enabling faster industry transitions, and fostering collaborations that scale biocatalytic impact globally.[2][6]
Zymvol is poised for expansion with its €3M seed fueling platform scaling and industry partnerships, targeting broader biocatalysis adoption amid AI-driven protein engineering trends.[5][7] Expect growth in high-value applications like novel materials and therapeutics, shaped by advancing AI models and regulatory tailwinds for green tech. Its influence could evolve from niche innovator to ecosystem enabler, powering sustainable R&D as chemical giants pivot—reinforcing its mission to make green chemistry the default since day one.[2][3]
Zymvol Biomodeling has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $3.0M Seed | Austin Walne, Elkstone, Faber, LGF, Pareto Holdings |